Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST Therapy in Relapsed/Refractory Pineoblastoma
NCT02596828Phase 2Completed
- Sponsor
- University of Regensburg
- Start
- Apr 2016
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Nanoparticles, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, nab-sirolimus in pineoblastoma (PB), sponsored by University of Regensburg. Started Apr 2016; status: completed.
02
Drugs
dasatinibnab-sirolimus
03
Conditions
pineoblastoma (PB)
Beyond the preview
Go deeper on NCT02596828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596828.